The Relationship Between Packaging And The Patient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relationship Between Packaging And The Patient


Pharmaceutical Technology Europe
Volume 23, Issue 5

This article is part of a special feature on packaging that was published in the May issue of PTE Digital, available at http://www.pharmtech.com/ptedigital0511.


Tim Clarke, CEO, healthcare and technology, at Burgopak Ltd.
In light of the challenges facing the pharma industry, such as changing patient demands and changing demographics, the relationship between the packaging, the consumer, and the product is being completely reconsidered as marketing and brand managers realise how beneficial well-designed packaging can be. For OTC products, good packaging can improve brand communication in a highly competitive market. If packaging is attractive, interactive, portable and a helpful reference, then the user is more likely to build a positive response to the product. Packaging that is not user friendly or that does not clearly communicate the added benefits of the medicine, will hold the brand back.

First impressions are crucial. When a consumer receives a product, their first interaction before taking the medicine is the packaging. Packaging that distracts the patient from thinking about their illness, but focuses them on the benefits of taking the medication is key. Think like a patient. What does the packaging say to them? Is it easy to use? Environmentally friendly? Well designed with clear communication? These are a few of thoughts that take place before the medicine has even been used. Smart packaging can help to make the patient feel more secure and well informed, and this can help improve compliance, which is a big issue in the pharma industry.

Industry issues

One problem with traditional medical packaging is that the leaflet, medicine and outer carton are separate components. Patient information leaflets are usually large once opened up and are almost impossible to reassemble back into the outer carton! Leaflets may then be discarded, leaving the patient with no reference point if they have any concerns regarding the medication they are taking. This can result in the patient not taking the medication correctly and prolonging their illness. Intelligent packaging design that is user friendly, functional and influences the patient to interact with the packaging helps support compliance.

One big issue for the pharma industry is general regulation, which is ever changing and becoming more stringent. In the area of packaging, however, the regulatory requirements for text and graphics have remained largely unchanged for many years, with the one notable exception of the mandate to include Braille on the outer carton. In the highly competitive market of OTC packaging, regulators, such as the UK's Medicines and Healthcare products Regulatory Agency, do appear to be getting stricter about not over-emphasising a product's benefits through claims such as "Max. Strength" and "Faster Acting".

Another problem in the industry is counterfeiting. Most pharma companies have adopted covert solutions to tackle this problem. However, packaging differentiation can also play a role. If a package is innovative and more difficult to produce than traditional packets and cartons, it may discourage counterfeiting.

Some packaging solutions are available that address all of these issues in a single pack; ultimately, improving patient compliance, discouraging counterfeiting and keeping the manufacturer's brand in front of the patient.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here